Ticker brief
CDT
last close
·
1 day
·
14 days
·
mkt cap
·
signals 14d
8
authors 14d
4
crowd 14d
-1.2σ
No price history on file for this name (likely non-equity or unlisted) — the “since then” column below stays blank.
Sentiment — last 14 days
daily mean sentiment, 2026-10-14 → 2026-10-16 · now +0.35 (−1 bearish … +1 bullish)
Who spoke4
| author | grade | trader score | signals | mean sent |
|---|---|---|---|---|
| @Tickeron | C | +1.53 | 4 | -0.57 |
| @PrismMarketView | C | · | 2 | -0.35 |
| @BPharmCatalyst | C | · | 1 | +0.25 |
| @smith_will86715 | C | -3.74 | 1 | +0.35 |
Recent signals8of 8 in 14d — receipts included
| date (PT) | author | sent | what they said | since then | receipt |
|---|---|---|---|---|---|
| 2026-10-16 | @smith_will86715 | +0.35 | Reports CDT moving at $0.19. | · | tweet ↗ |
| 2026-10-15 | @Tickeron | -0.65 | CDT faces dilution and listing risks while YRD faces governance uncertainty. | · | tweet ↗ |
| 2026-10-14 | @BPharmCatalyst | +0.25 | CDT portfolio company Sarborg files a patent and prepares testing and partnering work. | · | tweet ↗ |
| 2026-10-14 | @Tickeron | -0.45 | Describes two volatile micro-caps with sharp declines and speculative strategic pivots. | · | tweet ↗ |
| 2026-10-14 | @Tickeron | -0.65 | Notes BMBL's take-private support while emphasizing severe structural risks at CDT. | · | tweet ↗ |
| 2026-10-14 | @Tickeron | -0.55 | Contrasts patent-driven AIXI volatility with CDT's clinical-development and low-cash risks. | · | tweet ↗ |
| 2026-10-14 | @PrismMarketView | -0.70 | Premarket mover list gives percentage gains and losses. | · | tweet ↗ |
| 2026-10-14 | @PrismMarketView | +0.00 | Lists timestamped premarket gainers and decliners with percentage moves. | · | tweet ↗ |
“Since then” = price move from the close on the signal's date (PT) to the latest close — what happened after they said it, not a backtest. A — means no trading session has closed since the signal yet. Sentiment is our extracted per-tweet score, −1…+1.